Search Results 451-460 of 11347 for lamotrigine

  1. Carbidopa, entacapone, and levodopa (oral route) - Side effects & dosage - Mayo Clinic

    This medicine is also used to replace carbidopa and levodopa combination treatment (without entacapone) in patients who have end-of-dose "wearing-off" of drug ...

  2. https://www.mayoclinic.org/~/media/0439A7376021433E8FB3180F95C8FF95

  3. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo) - Mayo Clinic

    A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) ...

  4. Mental health: Overcoming the stigma of mental illness - Mayo Clinic

    Learn how to spot and deal with negative beliefs that some people have about mental health conditions. Don't let stigma stand in the way of getting ...

  5. Lenalidomide And AT-101 In Treating Patients With Relapsed Or Refractory B-Cell Chronic Lymphocytic Leukemia - Mayo Clinic

    Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, ...

  6. Desipramine (oral route) - Side effects & dosage - Mayo Clinic

    Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you ...

  7. Marnetegragene autotemcel (intravenous route) - Side effects & uses - Mayo Clinic

    Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you ...

  9. Glatiramer (subcutaneous route) - Side effects & dosage - Mayo Clinic

    Glatiramer injection is used to treat relapsing-forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and ...

  10. Evaluation of the changes in glycemic and physiologic parameters (sleep, cardioadapatbility parameters) in non-diabetic patients being treated for obesity with GLP1 Agonist and GLP-1/ GIP agonist medications. - Mayo Clinic

    Glycemic control will be monitored using the Ultrahuman M1(UH-M1) continuous glucose monitoring system, while sleep and activity will be measured by the ...